Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

midwives

- PMLiVE

NICE backs Sanofi’s Kevzara for routine NHS use

Recommends the RA treatment in combination with methotrexate

Content Shock

Is your content good enough to power your multi-channel marketing?

Content shock is the time when increasing volumes of content intersect our limited human capacity to consume it.

An agency called Owen

Sanofi reception

Sanofi, Regeneron claim EU approval for eczema drug Dupixent

Analysts suggest the product could be worth €5bn at peak

- PMLiVE

Sanofi looks to mobile data to power behavioural analysis

Teams up with Evidation Health for a new digital health partnership

- PMLiVE

Sanofi Genzyme brings The World Vs MS to Denmark

Firm's Communiqué Award winning campaign launches in another local market

How to choose your digital channels

Like any other areas of marketing, pharma digital communication is subject to fashion. A new technology arrives, people naturally get excited. Meanwhile, established communication technologies receive less focus (even if...

Anthill Agency

- PMLiVE

Navigating the social media waters in healthcare

Regulations shouldn't prevent creative and engaging social media content

- PMLiVE

Being social – harnessing the power of social media

With around 2.8 billion people using social media today, it’s a powerful force – one that encompasses a broad spectrum of websites and applications. In addition to well-known websites like Facebook,...

Porterhouse Medical Group

Sanofi reception

Solid start for Dupixent as Sanofi raises 2017 outlook

Analysts predict dermatology medicine could become a €5bn product if approved in other indications

The Pharma Multi-channel Marketing Maturity Model

The Pharma Multi-channel Marketing Maturity Model

Download our Pharma Multi-channel Marketing Maturity Model which provides a useful one-page ready-reckoner to see where you are on your multi-channel marketing journey.

An agency called Owen

- PMLiVE

Sanofi and Regeneron win CHMP nod for Dupixent

Atopic dermatitis treatment backed for European approval

Sanofi reception

Sanofi and Ablynx sign €2.4bn nanobody deal

The duo will develop immune-mediated inflammatory disease candidates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links